CHAPTER 3: Classification and coding
The Cancer Incidence in Five Continents (CI5) series has followed the evolution of the International Classification of Diseases (ICD) through four revisions, from the seventh revision (ICD 7) to the tenth (ICD 10), and the creation of a coding scheme for oncology: the International Classification of Diseases for Oncology (ICD O) (WHO, 1976), now in its third edition (ICD-O-3) (Fritz et al., 2000), which is available from http://codes.iarc.fr/. CI5 Volumes I (Doll et al., 1966) and II (Doll et al., 1970) presented data on cancer incidence coded to ICD-7 (WHO, 1957). Volume III (Waterhouse et al., 1976) published data using both ICD-7 and ICD-8 (WHO, 1967). ICD-8, which came into effect in 1968, was also used in Volume IV (Waterhouse et al., 1982). ICD-9 (WHO, 1977) was used for Volumes V (Muir et al., 1987), VI (Parkin et al., 1992), and VII (Parkin et al., 1997). ICD-10 (WHO, 1992) was used for Volumes VIII (Parkin et al., 2002), IX (Curado et al., 2007), and X (Forman et al., 2014).
The updates to ICD-10 (version 2010 available from http://www.who.int/classifications/icd/icd10updates/en/) and the 2011 revision of ICD-O-3 (WHO, 2013; available from http://codes.iarc.fr/) were considered in this volume, which presents data for the 5 year period of 2008–2012. The data are published at the level of the three-character ICD-10 codes in the individual registry tables. The groupings of ICD codes adopted in the previous three volumes have been used again in this volume to maintain comparability over time. Table 3.1 presents the individual ICD-10 site codes, the full ICD-10 titles, the Volume XI groupings, and the short titles used in the tables of incidence.
Updates of ICD-10 and ICD-O-3
The update of ICD-10 introduced in 2010 resulted in changes for the neoplasm chapter which affected the “Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue (C81-C96)” group. Mainly, a new 3-digit category C86 “Other specified types of T/NK-cell lymphoma” and several new 4-digit codes were added to the existing ones, and in particular the new code C88.4 “Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma], lymphoma of skin-associated lymphoid tissue (SALT-lymphoma) and lymphoma of bronchial-associated lymphoid tissue (BALT-lymphoma)”. These diagnoses were previously included within the ICD-10 (1990) C82.7 category in Volume X.
The 2011 revision of ICD-O-3 affected the morphology numerical list only, introducing new terms that have appeared in the recent literature particularly in the lymphoma and leukaemia group. Therefore, a new conversion table from ICD-O-3 first revision (2011) to ICD-10 (2010 version) for the ICD-O-3 morphology codes 9590/3 to 9992/3 had to be developed (see Table 3.2).
Classifications used in the cancer registry
Data submitted for the first four volumes of CI5 were sent in tabular format – organized by sex, site, and 5-year age group – on tape, diskette, or (most commonly) forms specifically designed for the purpose. The only verification possible was to tally the columns and rows. For Volume V, registries were given the option of sending data in the form of a case listing coded to ICD-9 topography only, or to ICD-9 or ICD-O topography plus ICD-O morphology. Only a very small minority of registries sent data coded to ICD-O. Contributors to Volume VI were encouraged to send data as a listing of individual cases, but 24% still sent tabulated data. Starting from Volume VII, data had to be sent as a listing of individual cases. Since the publication in 1976 of the first edition of ICD-O – which clearly defined axes of anatomical location, histology, and behaviour – international conformity to standard classification systems and coding rules has increased steadily. For data published in Volume IV (1973–1977), 90% of registries recorded histological diagnosis. For coding, just over a third of the registries used the American Cancer Society’s Manual of Tumor Nomenclature and Coding (MOTNAC) (ACS, 1951; 1968), a third had started to use ICD-O, and 12% used the Systematized Nomenclature of Pathology (SNOP) (CAP, 1965). About 75% of contributors to Volume V used ICD-O to code histology, and that proportion rose to more than 90% for Volumes VI and VII. Only 4 of the 186 contributors to Volume VIII, 1 of the 225 contributors to Volume IX, 2 of the 290 contributors to Volume X and all contributors to the present volume coded their histological data to ICD-O. Although most of the data submitted for this volume had been coded or converted to ICD-O-3 (see Chapter 6), registries were also asked what classification systems were used for coding data in the registry during the period. Of the 343 contributors, 326 registries (95%) coded to ICD-O topography and morphology (of which 319 used ICD-O-3), 17 registries (5%) coded to ICD-10 topography and ICD-O morphology.
Comparability
All data supplied for this volume either were already coded to ICD-O-3 when submitted, or were converted by IARC to ICD-O-3 for checking, and were then converted to ICD-10 for presentation (see Chapter 6). This process ensures that the same validity checks and multiple primary rules are applied to all data, and that the final ICD-10 codes used in this publication follow a standard ICD-O-3 to ICD-10 (2010 version) conversion. When a dataset included an ICD-10 code, this was ignored in the tabulations. The ICD-O-3 to ICD-10 conversion program was written at IARC using the rules of the ICD-O-2 to ICD-10 conversion program developed by Percy (1998). The conversions strictly follow the ICD 10 coding rules, as expressed in the instruction manual of ICD-10 Volume 2 (Percy et al., 1990) or in the alphabetical index of ICD-10 Volume 3. For example, the combination of unknown primary site (ICD-O-3 topography C80.9) and fibrosarcoma, not otherwise specified (NOS; ICD-O-3 morphology 8810/3) is converted to C49.9: “Connective and other soft tissues, NOS” in ICD-10 (see ICD-10 Volume 2, page 74).
Theoretically, the use of a standard, well-designed coding system such as ICD should make the analysis and tabulation of comparable results a simple matter. But in practice, it has been a continual exercise in detection for the editors of CI5 to establish exactly how registries code various cancers. For the present volume, registries were asked whether any malignant diagnoses were excluded from their data, and how they coded intraductal carcinoma of breast, NOS; ductal and lobular carcinoma in situ of breast; ovarian cystadenoma of borderline malignancy; borderline tumour of ovary; benign tumours of brain and nervous system; and in situ and unspecified carcinoma of bladder.
Non-melanoma skin cancer
The incidence of non-melanoma skin cancer (NMSC) is difficult to assess. These cancers are very common and rarely fatal, and the completeness of their registration varies widely depending on access to outpatient and general practitioners’ records. Most NMSCs are basal cell carcinomas (BCCs) or squamous cell carcinomas (SCCs); other skin cancers are rare. Although some registries record the first occurrence of all NMSCs, others register BCC only , and many do not collect data on either SCC or BCC.
Bladder cancer
The issue of coding non-invasive tumours (taking into account the recorded level of invasion and grade) – and which to include in the tables as “cancer of the bladder” – has long been a subject of debate. In CI5 Volume VI, it was decided, for the sake of geographical comparability, to exclude tumours of benign, in situ, and unspecified behaviour. In principle, the availability of data as individual case listings with histological type and behaviour should make it possible to publish only data on malignant cancer, by excluding diagnoses with any behaviour code other than /3. But when registries were asked about the behaviour codes they used for non-invasive and unspecified diagnoses of malignant bladder cancer for Volume VII, many of them reported that they assigned the behaviour code /3 to both in situ and unspecified diagnoses, making it impossible to distinguish such cases. As a result, the editors decided to accept that non-invasive diagnoses of bladder cancer are generally considered malignant by pathologists; since Volume VII, the bladder cancer rubric (ICD-10 C67) has therefore included the in situ (ICD 10 D09.0) and unspecified (ICD 10 D41.4) categories. In this volume, whenever possible, the inclusion of neoplasms of uncertain or unknown behaviour together with invasive cancers is indicated by a dagger symbol beside C67 in the tables, and a note on the data in the accompanying narrative. A few registries preferred not to include such cases in their dataset, even when available in the registry, for the sake of continuity over time.
Breast cancer
Intraductal carcinoma, ductal carcinoma in situ (DCIS), and lobular carcinoma in situ of breast are classified in ICD-O-3 as in situ cancers (behaviour code /2). All the registries in CI5 Volume XI collect these diagnoses.
Ovarian cancer
The registries contributing to this volume were asked how they coded ovarian cystadenoma of borderline malignancy and borderline tumour of ovary. Borderline ovarian diagnoses are classified as non-malignant tumours in ICD-O-3 (behaviour code /1) and are excluded from the tabulations, but a few registries still code them as malignant neoplasms.
Brain and central nervous system
Many registries choose to include benign and unspecified tumours of the brain and central nervous system in their data, because of the potentially serious clinical consequences of these tumours. Prior to Volume VII, such tumours may therefore have been included in the tables along with cancers of the brain and nervous system. However, the proportion of such cases varies widely between registries, so since Volume VII they are no longer included.
Myeloproliferative disorders and myelodysplastic syndromes
These include records with the ICD-O-3 morphological codes 9950/3, 996_/3, 9971/3, 9975/3, 998_/3 and 999_/3. Only registries that originally coded their data to ICD-O-3 can report such diagnoses, as they were not considered malignant tumours in ICD-O-2 (behaviour code /1). These codes are converted to the ICD-10 codes D45, D46_, and D47_ by the IARC ICD O-3 to ICD-10 conversion program (except M9966/3, M9967/3 and M9984/3 which are converted to ICD-10 C92.7, C96.7 and C92.0 respectively, see Table 3.2), and are presented in two separate categories in the tables “Myeloproliferative disorders (MPD)” and “Myelodysplastic syndromes (MDS)” and also included in the “All sites (C00-96)” category.
| Table 3.1. Classification used in the incidence tables in CI5 Volume XI | |||
|---|---|---|---|
| ICD-10 (version 2010) site code | Full ICD-10 title | Grouping used in tables | Short title used in tables |
| C00 | Malignant neoplasm of lip | – | Lip |
| C01 | Malignant neoplasm of base of tongue | C01–C02 are grouped | Tongue |
| C02 | Malignant neoplasm of other and unspecified parts of tongue | ||
| C03 | Malignant neoplasm of gum | C03–C06 are grouped | Mouth |
| C04 | Malignant neoplasm of floor of mouth | ||
| C05 | Malignant neoplasm of palate | ||
| C06 | Malignant neoplasm of other and unspecified parts of mouth | ||
| C07 | Malignant neoplasm of parotid gland | C07–C08 are grouped | Salivary gland |
| C08 | Malignant neoplasm of other and unspecified major salivary glands | ||
| C09 | Malignant neoplasm of tonsil | – | Tonsil |
| C10 | Malignant neoplasm of oropharynx | – | Other oropharynx |
| C11 | Malignant neoplasm of nasopharynx | – | Nasopharynx |
| C12 | Malignant neoplasm of pyriform sinus | C12–C13 are grouped | Hypopharynx |
| C13 | Malignant neoplasm of hypopharynx | ||
| C14 | Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx | – | Pharynx unspecified |
| C15 | Malignant neoplasm of oesophagus | – | Oesophagus |
| C16 | Malignant neoplasm of stomach | – | Stomach |
| C17 | Malignant neoplasm of small intestine | – | Small intestine |
| C18 | Malignant neoplasm of colon | – | Colon |
| C19 | Malignant neoplasm of rectosigmoid junction | C19–C20 are grouped | Rectum |
| C20 | Malignant neoplasm of rectum | ||
| C21 | Malignant neoplasm of anus and anal canal | – | Anus |
| C22 | Malignant neoplasm of liver and intrahepatic bile ducts | – | Liver |
| C23 | Malignant neoplasm of gallbladder | C23–C24 are grouped | Gallbladder etc. |
| C24 | Malignant neoplasm of other and unspecified parts of biliary tract | ||
| C25 | Malignant neoplasm of pancreas | – | Pancreas |
| C26 | Malignant neoplasm of other and ill-defined digestive organs | C26 is included in other and unspecified malignant neoplasms | |
| C30 | Malignant neoplasm of nasal cavity and middle ear | C30–C31 are grouped | Nose, sinuses, etc. |
| C31 | Malignant neoplasm of accessory sinuses | ||
| C32 | Malignant neoplasm of larynx | – | Larynx |
| C33 | Malignant neoplasm of trachea | C33–C34 are grouped | Trachea, bronchus, and lung |
| C34 | Malignant neoplasm of bronchus and lung | ||
| C37 | Malignant neoplasm of thymus | C37–C38 are grouped | Other thoracic organs |
| C38 | Malignant neoplasm of heart, mediastinum and pleura | ||
| C39 | Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs | C39 is included in other and unspecified malignant neoplasms | |
| C40 | Malignant neoplasm of bone and articular cartilage of limbs | C40–C41 are grouped | Bone |
| C41 | Malignant neoplasm of bone and articular cartilage of other and unspecified sites | ||
| C43 | Malignant melanoma of skin | – | Melanoma of skin |
| C44 | Other malignant neoplasms of skin | – | Other skin |
| C45 | Mesothelioma | – | Mesothelioma |
| C46 | Kaposi sarcoma | – | Kaposi sarcoma |
| C47 | Malignant neoplasm of peripheral nerves and autonomic nervous system | C47 is grouped with C49 | Connective and soft tissue |
| C48 | Malignant neoplasm of retroperitoneum and peritoneum | C48 is included in other and unspecified malignant neoplasms | |
| C49 | Malignant neoplasm of other connective and soft tissue | C49 is grouped with C47 | |
| C50 | Malignant neoplasm of breast | – | Breast |
| C51 | Malignant neoplasm of vulva | – | Vulva |
| C52 | Malignant neoplasm of vagina | – | Vagina |
| C53 | Malignant neoplasm of cervix uteri | – | Cervix uteri |
| C54 | Malignant neoplasm of corpus uteri | – | Corpus uteri |
| C55 | Malignant neoplasm of uterus, part unspecified | – | Uterus unspecified |
| C56 | Malignant neoplasm of ovary | – | Ovary |
| C57 | Malignant neoplasm of other and unspecified female genital organs | – | Other female genital organs |
| C58 | Malignant neoplasm of placenta | – | Placenta |
| C60 | Malignant neoplasm of penis | – | Penis |
| C61 | Malignant neoplasm of prostate | – | Prostate |
| C62 | Malignant neoplasm of testis | – | Testis |
| C63 | Malignant neoplasm of other and unspecified male genital organs | – | Other male genital organs |
| C64 | Malignant neoplasm of kidney, except renal pelvis | – | Kidney |
| C65 | Malignant neoplasm of renal pelvis | – | Renal pelvis |
| C66 | Malignant neoplasm of ureter | – | Ureter |
| C67 | Malignant neoplasm of bladder | – | Bladder |
| C68 | Malignant neoplasm of other and unspecified urinary organs | – | Other urinary organs |
| C69 | Malignant neoplasm of eye and adnexa | – | Eye |
| C70 | Malignant neoplasm of meninges | C70–C72 are grouped | Brain and nervous system |
| C71 | Malignant neoplasm of brain | ||
| C72 | Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system | ||
| C73 | Malignant neoplasm of thyroid gland | – | Thyroid |
| C74 | Malignant neoplasm of adrenal gland | – | Adrenal gland |
| C75 | Malignant neoplasm of other endocrine glands and related structures | – | Other endocrine |
| C76 | Malignant neoplasm of other and ill-defined sites | C76 is included in other and unspecified malignant neoplasms | |
| C80 | Malignant neoplasm, without specification of site | C80 is included in other and unspecified malignant neoplasms | |
| C81 | Hodgkin lymphoma | – | Hodgkin lymphoma |
| C82 | Follicular lymphoma | C82–C86 and C96 are grouped | Non-Hodgkin lymphoma |
| C83 | Non-Follicular lymphoma | ||
| C84 | Mature T/NK-cell lymphomas | ||
| C85 | Other and unspecified types of non-Hodgkin lymphoma | ||
| C86 | Other specified types of T/NK-cell lymphoma | ||
| C88 | Malignant immunoproliferative diseases | – | Immunoproliferative diseases |
| C90 | Multiple myeloma and malignant plasma cell neoplasms | – | Multiple myeloma |
| C91 | Lymphoid leukaemia | – | Lymphoid leukaemia |
| C92 | Myeloid leukaemia | C92–C94 are grouped (following ICD-O-3) | Myeloid leukaemia |
| C93 | Monocytic leukaemia | ||
| C94 | Other leukaemias of specified cell type | ||
| C95 | Leukaemia of unspecified cell type | – | Leukaemia unspecified |
| C96 | Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue | C96 is grouped with C82–C86 | |
| O&U | Other and unspecified malignant neoplasms | Includes C26, C39, C48, C76, and C80 | Other and unspecified |
| MPD | Myeloproliferative disorders | Includes ICD-O-3 M9950/3, M9960-M9965/3, M9971/3 and M9975/3 | Myeloproliferative disorders |
| MDS | Myelodysplastic syndromes | Includes ICD-O-3 M9980-9983/3,M9985-9989/3, M9991/3 and M9992/3 | Myelodysplastic syndromes |
| C00-96* | All sites | ||
| C00-96* exc. C44 | All sites except C44 | ||
| *Includes O&U, MPD and MDS site codes | |||
| Table 3.2. Conversion of lymphoid and haematopoietic diseases (ICD-O-3 M9590-M9992) | ||
|---|---|---|
| ICD-O-3 (first revision) code | Full ICD-O-3 title | ICD-10 (version 2010) site code |
| Malignant lymphomas, NOS or diffuse | ||
| 9590/3 | Malignant lymphoma, NOS | C85.9 |
| 9591/3 | Malignant lymphoma, non-Hodgkin, NOS | C85.9 |
| 9596/3 | Composite Hodgkin and non-Hodgkin lymphoma | C85.1 |
| 9597/3 | Primary cutaneous follicle centre lymphoma | C82.6 |
| Hodgkin lymphoma | ||
| 9650/3 | Hodgkin lymphoma, NOS | C81.9 |
| 9651/3 | Hodgkin lymphoma, lymphocyte-rich | C81.4 |
| 9652/3 | Hodgkin lymphoma, mixed cellularity, NOS | C81.2 |
| 9653/3 | Hodgkin lymphoma, lymphocyte depletion, NOS | C81.3 |
| 9654/3 | Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis | C81.3 |
| 9655/3 | Hodgkin lymphoma, lymphocyte depletion, reticular | C81.3 |
| 9659/3 | Hodgkin lymphoma, nodular lymphocyte predominance | C81.0 |
| 9661/3 | Hodgkin granuloma | C81.9 |
| 9662/3 | Hodgkin sarcoma | C81.3 |
| 9663/3 | Hodgkin lymphoma, nodular sclerosis, NOS | C81.1 |
| 9664/3 | Hodgkin lymphoma, nodular sclerosis, cellular phase | C81.1 |
| 9665/3 | Hodgkin lymphoma, nodular sclerosis, grade 1 | C81.1 |
| 9667/3 | Hodgkin lymphoma, nodular sclerosis, grade 2 | C81.1 |
| Mature B-cell lymphomas | ||
| 9670/3 | Malignant lymphoma, small B lymphocytic, NOS | C83.0 |
| 9671/3 | Malignant lymphoma, lymphoplasmacytic | C83.0 |
| 9673/3 | Mantle cell lymphoma | C83.1 |
| 9675/3 | Malignant lymphoma, mixed small and large cell, diffuse | C85.9 |
| 9678/3 | Primary effusion lymphoma | C83.8 |
| 9679/3 | Mediastinal large B-cell lymphoma (C38.3) | C85.2 |
| 9680/3 | Malignant lymphoma, large B-cell, diffuse, NOS | C83.3 |
| 9684/3 | Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS | C83.3 |
| 9687/3 | Burkitt lymphoma, NOS | C83.7 |
| 9688/3 | T-cell/histiocyte rich large B-cell lymphoma | C83.3 |
| 9689/3 | Splenic marginal zone B-cell lymphoma (C42.2) | C83.0 |
| 9690/3 | Follicular lymphoma, NOS | C82.9 |
| 9691/3 | Follicular lymphoma, grade 2 | C82.1 |
| 9695/3 | Follicular lymphoma, grade 1 | C82.0 |
| 9698/3 | Follicular lymphoma, grade 3 | C82.2 |
| 9699/3 | Marginal zone B-cell lymphoma, NOS | C83.0 (C42.0; C42.1; C42.4, C77._) C88.4 (other topography) |
| Mature T- and NK-cell lymphomas | ||
| 9700/3 | Mycosis fungoides (C44._) | C84.0 |
| 9701/3 | Sezary syndrome | C84.1 |
| 9702/3 | Mature T-cell lymphoma, NOS | C84.4 |
| 9705/3 | Angioimmunoblastic T-cell lymphoma | C86.5 |
| 9708/3 | Subcutaneous panniculitis-like T-cell lymphoma | C86.3 |
| 9709/3 | Cutaneous T-cell lymphoma, NOS (C44._) | C84.8 |
| 9712/3 | Intravascular large B-cell lymphoma (C49.9) | C83.8 |
| 9714/3 | Anaplastic large cell lymphoma, T cell and Null cell type | C84.6 |
| 9716/3 | Hepatosplenic T-cell lymphoma | C86.1 |
| 9717/3 | Intestinal T-cell lymphoma | C86.2 |
| 9718/3 | Primary cutaneous CD30+ T-cell lymphoproliferative disorder (C44._) | C86.6 |
| 9719/3 | NK/T-cell lymphoma, nasal and nasal-type | C86.0 |
| Precursor cell lymphoblastic lymphoma | ||
| 9724/3 | Systemic EBV positive T-cell lymphoproliferative disease of childhood | C84.5 |
| 9725/3 | Hydroa vacciniforme-like lymphoma | C84.5 |
| 9726/3 | Primary cutaneous gamma-delta T-cell lymphoma | C84.5 |
| 9727/3 | Precursor cell lymphoblastic lymphoma, NOS | C83.5* |
| 9728/3 | Precursor B-cell lymphoblastic lymphoma | C83.5 |
| 9729/3 | Precursor T-cell lymphoblastic lymphoma | C83.5 |
| Plasma cell tumors | ||
| 9731/3 | Plasmacytoma, NOS | C90.3 |
| 9732/3 | Multiple myeloma (C42.1) | C90.0 |
| 9733/3 | Plasma cell leukemia (C42.1) | C90.1 |
| 9734/3 | Plasmacytoma, extramedullary | C90.2 |
| 9735/3 | Plasmablastic lymphoma | C83.3 |
| 9737/3 | ALK positive large B-cell lymphoma | C83.3 |
| 9738/3 | Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease | C83.3 |
| Mast cell tumors | ||
| 9740/1 | Mastocytoma, NOS | D47.0 |
| 9740/3 | Mast cell sarcoma | C96.2 |
| 9741/1 | Indolent systemic mastocytosis | D47.0 |
| 9741/3 | Malignant mastocytosis | C96.2 |
| 9742/3 | Mast cell leukemia (C42.1) | C94.3 |
| Neoplasms of histiocytes and accessory lymphoid cells | ||
| 9750/3 | Malignant histiocytosis | C96.8 |
| 9751/3 | Langerhans cell histiocytosis, NOS | C96.6 |
| 9755/3 | Histiocytic sarcoma | C96.8 |
| 9756/3 | Langerhans cell sarcoma | C96.4 |
| 9757/3 | Interdigitating dendritic cell sarcoma | C96.4 |
| 9758/3 | Follicular dendritic cell sarcoma | C96.4 |
| 9759/3 | Fibroblastic reticular cell tumor | C96.4 |
| Immunoproliferative diseases | ||
| 9760/3 | Immunoproliferative disease, NOS | C88.9 |
| 9761/3 | Waldenstrom macroglobulinemia (C42.0) | C88.0 |
| 9762/3 | Heavy chain disease, NOS | C88.2 |
| 9764/3 | Immunoproliferative small intestinal disease (C17._) | C88.3 |
| 9765/1 | Monoclonal gammopathy of undetermined significance | D47.2 |
| 9766/1 | Angiocentric immunoproliferative lesion | C83.8 |
| 9766/3# | Angiocentric immunoproliferative lesion | C83.8 |
| 9767/1 | Angioimmunoblastic lymphadenopathy (AIC) | C86.5 |
| 9767/3# | Angioimmunoblastic lymphadenopathy (AIC) | C86.5 |
| 9768/1 | T-gamma lymphoproliferative disease | D47.9 |
| 9769/1 | Immunoglobulin deposition disease | D47.7 |
| Leukemias, NOS | ||
| 9800/3 | Leukemia, NOS | C95.9 |
| 9801/3 | Acute leukemia, NOS | C95.0 |
| 9805/3 | Acute biphenotypic leukemia | C95.0 |
| 9806/3 | Mixed phenotype acute leukemia with t(9;22)(q34;q11.2);BCR-ABL1 | C95.0 |
| 9807/3 | Mixed phenotype acute leukemia with t(v;11q23);MLL rearranged | C95.0 |
| 9808/3 | Mixed phenotype acute leukemia, B/myeloid, NOS | C95.0 |
| 9809/3 | Mixed phenotype acute leukemia, T/myeloid, NOS | C95.0 |
| Lymphoid leukemias | ||
| 9811/3 | B lymphoblastic leukemia/lymphoma, NOS | C91.0 |
| 9812/3 | B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2);BCR-ABL1 | C91.0 |
| 9813/3 | B lymphoblastic leukemia/lymphoma with t(v;11q23);MLL rearranged | C91.0 |
| 9814/3 | B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22);TEL-AML1 (ETV6-RUNX1) | C91.0 |
| 9815/3 | B lymphoblastic leukemia/lymphoma with hyperdiploidy | C91.0 |
| 9816/3 | B lymphoblastic leukemia/lymphoma with hypodiploidy (hypodiploid ALL) | C91.0 |
| 9817/3 | B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32);IL3-IGH | C91.0 |
| 9818/3 | B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3);E2A PBX1 (TCF3 PBX1) | C91.0 |
| 9820/3 | Lymphoid leukemia, NOS | C91.9 |
| 9823/3 | B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma | C91.1 |
| 9826/3 | Burkitt cell leukemia | C91.8 |
| 9827/3 | Adult T-cell leukemia/lymphoma (HTLV-1 positive) | C91.5 |
| 9831/3 | T-cell large granular lymphocytic leukemia | C91.7 |
| 9832/3 | Prolymphocytic leukemia, NOS | C91.3 |
| 9833/3 | Prolymphocytic leukemia, B-cell type | C91.3 |
| 9834/3 | Prolymphocytic leukemia, T-cell type | C91.6 |
| 9835/3 | Precursor cell lymphoblastic leukemia, NOS | C91.0 |
| 9836/3 | Precursor B-cell lymphoblastic leukemia | C91.0 |
| 9837/3 | T lymphoblastic leukemia/lymphoma | C91.0 |
| Myeloid leukemias | ||
| 9840/3 | Acute myeloid leukemia, M6 type | C94.0 |
| 9860/3 | Myeloid leukemia, NOS | C92.9 |
| 9861/3 | Acute myeloid leukemia, NOS | C92.0 |
| 9863/3 | Chronic myeloid leukemia, NOS | C92.1 |
| 9865/3 | Acute myeloid leukemia with t(6;9)(p23;q34) DEK-NUP214 | C92.0 |
| 9866/3 | Acute promyelocytic leukemia, t(15;17)(q22;q11-12) | C92.4 |
| 9867/3 | Acute myelomonocytic leukemia | C92.5 |
| 9869/3 | Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2);RPN1-EVI1 | C92.0 |
| 9870/3 | Acute basophilic leukemia | C94.7 |
| 9871/3 | Acute myeloid leukemia with abnormal marrow eosinophils | C92.5 |
| 9872/3 | Acute myeloid leukemia, minimal differentiation | C92.0 |
| 9873/3 | Acute myeloid leukemia without maturation | C92.0 |
| 9874/3 | Acute myeloid leukemia with maturation | C92.0 |
| 9875/3 | Chronic myelogenous leukemia, BCR/ABL positive | C92.1 |
| 9876/3 | Atypical chronic myeloid leukemia, BCR/ABL negative | C92.2 |
| 9891/3 | Acute monocytic leukemia | C93.0 |
| 9895/3 | Acute myeloid leukemia with myelodysplasia-related changes | C92.8 |
| 9896/3 | Acute myeloid leukemia, t(8;21)(q22;q22) | C92.0 |
| 9897/3 | Acute myeloid leukemia, 11q23 abnormalities | C92.6 |
| 9898/1 | Transient abnormal myelopoiesis | D47.1 |
| 9898/3 | Myeloid leukemia associated with Down Syndrome | C92.7 |
| 9910/3 | Acute megakaryoblastic leukemia | C94.2 |
| 9911/3 | Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13);RBM15-MKL1 | C94.2 |
| 9920/3 | Therapy related myeloid neoplasm | C94.6 |
| 9930/3 | Myeloid sarcoma | C92.3 |
| 9931/3 | Acute panmyelosis with myelofibrosis (C42.1) | C94.4 |
| 9940/3 | Hairy cell leukemia (C42.1) | C91.4 |
| Other leukemias | ||
| 9945/3 | Chronic myelomonocytic leukemia, NOS | C93.1 |
| 9946/3 | Juvenile myelomonocytic leukemia | C93.3 |
| 9948/3 | Aggressive NK-cell leukemia | C94.7 |
| Chronic myeloproliferative disorders | ||
| 9950/3 | Polycythemia vera | D45/MPD |
| 9960/3 | Myeloproliferative neoplasm, NOS | D47.1/MPD |
| 9961/3 | Primary myelofibrosis | D47.4/MPD |
| 9962/3 | Essential thrombocythemia | D47.3/MPD |
| 9963/3 | Chronic neutrophilic leukemia | D47.1/MPD |
| 9964/3 | Chronic eosinophilic leukemia, NOS | D47.5/MPD |
| 9965/3 | Myeloid and lymphoid neoplasms with PDGFRA rearrangement | D47.5/MPD |
| 9966/3 | Myeloid neoplasms with PDGFRB rearrangement | C92.7 |
| 9967/3 | Myeloid and lymphoid neoplasms with FGFR1 abnormalities | C96.7 |
| Other hematologic disorders | ||
| 9971/3 | Polymorphic post transplant lymphoproliferative disorder | D47.7/MPD |
| 9975/3 | Myloproliferative neoplasm, unclassifiable | D47.1/MPD |
| Myelodysplastic syndromes | ||
| 9980/3 | Refractory anemia | D46.4/MDS |
| 9982/3 | Refractory anemia with sideroblasts | D46.1/MDS |
| 9983/3 | Refractory anemia with excess blasts | D46.2/MDS |
| 9984/3 | Refractory anemia with excess blasts in transformation | C92.0 |
| 9985/3 | Refractory cytopenia with multilineage dysplasia | D46.5/MDS |
| 9986/3 | Myelodysplastic syndrome with 5q deletion (5q-) syndrome | D46.6/MDS |
| 9987/3 | Therapy-related myelodysplastic syndrome, NOS | D46.7/MDS |
| 9989/3 | Myelodysplastic syndrome, NOS | D46.9/MDS |
| 9991/3 | Refractory neutropenia | D46.7/MDS |
| 9992/3 | Refractory thrombocytopenia | D46.7/MDS |
| *If used for “Blastic plasmacytoid dendritic cell neoplasm”, then convert to C86.4 | ||
| #Normally coded with a behaviour code /1, but few cases were reported with a behaviour code /3 | ||